SCHEMBL2237688

SCHEMBL2237688

Cc1cc(N(CC(=O)Nc2ccc(-c3ncon3)cc2)C(=O)C2CCS(=O)(=O)CC2)ccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 8/20 0.39
▸ HDAC8 Q9BY41 8/20 0.39
▸ HDAC6 Q9UBN7 8/20 0.39
▸ HDAC5 Q9UQL6 6/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ THRB P10828 1/20 0.33
▸ NR1I2 O75469 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ NR1H4 Q96RI1 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ POLB P06746 2/20 0.33
▸ ATM Q13315 1/20 0.33
▸ F11 P03951 1/20 0.33
▸ KLKB1 P03952 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21769572 0.94 POLB (0.38) HDAC1HDAC8HDAC6HDAC5SMN1; SMN2
SCHEMBL21769881 0.94 ALDH1A1 (0.39) HDAC1HDAC8HDAC6HDAC5SMN1; SMN2
SCHEMBL21769738 0.91 HDAC1 (0.39) HDAC1HDAC8HDAC6HDAC5MEN1
SCHEMBL21769855 0.90 MEN1 (0.39) HDAC1HDAC8HDAC6HDAC5MEN1
SCHEMBL2237823 0.90 HDAC1 (0.39) HDAC1HDAC8HDAC6HDAC5MEN1
SCHEMBL17923449 0.89 SMN1; SMN2 (0.36) SMN1; SMN2MEN1KMT2AL3MBTL1MAPT
SCHEMBL21769743 0.89 HDAC1 (0.38) HDAC1HDAC8HDAC6HDAC5L3MBTL1
SCHEMBL3557373 0.89 MAPT (0.36) HDAC1HDAC8HDAC6HDAC5SMN1; SMN2
SCHEMBL21769877 0.88 MAPT (0.41) HDAC1HDAC8HDAC6HDAC5SMN1; SMN2
SCHEMBL21769730 0.88 HDAC1 (0.42) HDAC1HDAC8HDAC6HDAC5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2263671-B1 AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION ASTELLAS PHARMA INC (JP) 2016-07-20 — — EP claimed
US-9050326-B2 Amido derivatives-contained pharmaceutical composition ASTELLAS PHARMA INC. (JP) 2015-06-09 — — US claimed
US-20110201659-A1 AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN ASTELLAS PHARMA INC. (JP) 2011-08-18 — — US claimed
EP-2263671-A1 AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION Astellas Pharma Inc. (JP) 2010-12-22 — — EP claimed
US-20090270463-A1 AMIDO DERIVATIVES-CONTAINED PHARMACEUTICAL COMPOSITION ASTELLAS PHARMA INC. (JP) 2009-10-29 — — US claimed
EP-1652843-A1 AMIDE DERIVATIVES Astellas Pharma Inc. (JP) 2006-05-03 — — EP claimed
US-6903125-B2 Tetrahydro-2H-thiopyran-4-carboxamide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-06-07 — — US claimed
US-20050032855-A1 Tetrahydro-2H-thiopyran-4-carboxamide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. 2005-02-10 — — US claimed
WO-2020038812-A1 NEW PROCESS FOR THE PREPARATION OF AMENAMEVIR RIJKSUNIVERSITEIT GRONINGEN (NL) 2020-02-27 — — WO disclosed
EP-2263671-B1 AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION ASTELLAS PHARMA INC (JP) 2016-07-20 — — EP disclosed
US-9050326-B2 Amido derivatives-contained pharmaceutical composition ASTELLAS PHARMA INC. (JP) 2015-06-09 — — US disclosed
US-20110201659-A1 AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN ASTELLAS PHARMA INC. (JP) 2011-08-18 — — US disclosed
EP-2351565-A1 MEDICINE FOR PREVENTING OR TREATING PAIN RELATED TO HERPES ZOSTER Astellas Pharma Inc. (JP) 2011-08-03 — — EP disclosed
EP-2263671-A1 AMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION Astellas Pharma Inc. (JP) 2010-12-22 — — EP disclosed
EP-1844775-A1 THERAPEUTIC AGENT FOR HERPES PROGENITALIS Astellas Pharma Inc. (JP) 2007-10-17 — — EP disclosed
EP-1844776-A1 AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS Astellas Pharma Inc. (JP) 2007-10-17 — — EP disclosed
US-20060229295-A1 Amide derivatives ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) 2006-10-12 — — US disclosed
EP-1652843-A1 AMIDE DERIVATIVES Astellas Pharma Inc. (JP) 2006-05-03 — — EP disclosed
US-6903125-B2 Tetrahydro-2H-thiopyran-4-carboxamide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-06-07 — — US disclosed
US-20050032855-A1 Tetrahydro-2H-thiopyran-4-carboxamide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. 2005-02-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270463-A1 AMIDO DERIVATIVES-CONTAINED PHARMACEUTICAL COMPOSITION ACMSD, ADM2, PAM HDAC1 968/4885HDAC8 731/4885HDAC6 263/4885
US-20050032855-A1 Tetrahydro-2H-thiopyran-4-carboxamide derivative TPMT, RPL35, TYMP HDAC1 39/4885HDAC8 32/4885HDAC6 1368/4885
US-20110201659-A1 AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN GAP43, TRPV1, ACHE HDAC1 1277/4885HDAC8 1199/4885HDAC6 771/4885
US-20060229295-A1 Amide derivatives VAC14, HDAC8, ZC3HAV1 HDAC1 7/4885HDAC8 2/4885HDAC6 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback